About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Dallas | 17,468 Studies Near You | Clareo Health

Clinical Trials LocationsDallas

Clinical Trials in Dallas

Discover 17,468 clinical trials near Dallas, Texas. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 4661-4680 of 17,468 trials

TERMINATEDPhase 1< 1 mile

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

NCT00529113

This study assesses the safety and efficacy of RTA 402 in combination with gemcitabine in patients with unresectable pancreatic cancer.

Pancreatic NeoplasmsPancreatic Cancer

Biogen33 participantsStarted Sep 2007

Denver, Colorado, United States • Ocoee, Florida, United States • Indianapolis, Indiana, United States +2 more locations

TERMINATEDPhase 2< 1 mile

RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

NCT00538343

The purpose of this study is to determine whether RTA 744 is effective in the treatment of breast cancer that has metastasized to the brain.

Brain Metastases

Biogen14 participantsStarted Oct 2007

West Palm Beach, Florida, United States • Charlotte, North Carolina, United States • Durham, North Carolina, United States +4 more locations

Find Trials by Condition in Dallas

Breast Cancerin Dallas Lung Cancerin Dallas Prostate Cancerin Dallas Colorectal Cancerin Dallas Melanomain Dallas Leukemiain Dallas Lymphomain Dallas Pancreatic Cancerin Dallas Ovarian Cancerin Dallas Brain Cancerin Dallas Diabetesin Dallas

Data from ClinicalTrials.govTerms

Active Not RecruitingPhase 1< 1 mile

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

NCT05704985

This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.

CancerSolid TumorColorectal Cancer+6 more

DEKA Biosciences39 participantsStarted Apr 2023

Duarte, California, United States • Manhasset, New York, United States • Oklahoma City, Oklahoma, United States +4 more locations

COMPLETEDPhase 1< 1 mile

A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas

NCT00526812

This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent high-grade gliomas.

Biogen54 participantsStarted Nov 2005

Los Angeles, California, United States • Dallas, Texas, United States • Dallas, Texas, United States +1 more locations

COMPLETEDPhase 1/2< 1 mile

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02713386

This phase I/II trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin and to see how well they work in treating patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate together with paclitaxel and carboplatin may be a better treatment for epithelial ovarian, fallopian tube, or primary peritoneal cancer compared to paclitaxel and carboplatin alone.

Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous Adenocarcinoma+23 more

NRG Oncology147 participantsStarted Nov 2016

Goodyear, Arizona, United States • Auburn, California, United States • Los Angeles, California, United States +107 more locations

COMPLETEDPhase 313 miles

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

NCT04456673

Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by * Annualized rate of acute moderate or severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effect of dupilumab administered every 2 weeks on * Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo * Health related quality of life, assessed by the change from baseline to Week 52 in the St. George's Respiratory Questionnaire (SGRQ) * Pre-bronchodilator FEV1 over 52 weeks compared to placebo * Lung function assessments * Moderate and severe COPD exacerbations * To evaluate safety and tolerability * To evaluate dupilumab systemic exposure and incidence of antidrug antibodies (ADA)

Chronic Obstructive Pulmonary Disease

Sanofi935 participantsStarted Jul 2020

Cullman, Alabama, United States • Jasper, Alabama, United States • Scottsboro, Alabama, United States +331 more locations

COMPLETEDPhase 217 miles

A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain

NCT05560646

The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.

Organon and Co354 participantsStarted Oct 2022

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Los Angeles, California, United States +83 more locations

COMPLETEDPhase 231 miles

An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism

NCT04538989

The objective of this trial is to evaluate the safety, tolerability and glucose-raising effects of RZ358 in patients with Congenital Hyperinsulinism (HI).

Congenital Hyperinsulinism

Rezolute23 participantsStarted Feb 2020

Philadelphia, Pennsylvania, United States • Fort Worth, Texas, United States • Sofia, Bulgaria +14 more locations

COMPLETEDPhase 231 miles

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants

NCT04215991

The primary objectives of this study are to assess the safety, tolerability, and pharmacokinetics (PK) of cefiderocol after single-dose administration in hospitalized pediatric participants 3 months to \< 12 years of age with suspected or confirmed aerobic Gram-negative bacterial infections and after multiple-dose administration in hospitalized pediatric participants 3 months to \< 18 years of age with suspected or confirmed complicated urinary tract infection (cUTI), hospital-acquired bacterial pneumonia (HABP), or ventilator-associated bacterial pneumonia (VABP).

Gram-negative Bacterial InfectionsHospital Acquired Bacterial Pneumonia (HABP)Complicated Urinary Tract Infection (cUTI)+1 more

Shionogi91 participantsStarted Feb 2020

Iowa City, Iowa, United States • Fort Worth, Texas, United States • South Brisbane, Queensland, Australia +22 more locations

COMPLETEDPhase 1182 miles

A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults

NCT05972993

The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines.

GlaxoSmithKline114 participantsStarted Aug 2023

San Diego, California, United States • Melbourne, Florida, United States • Peoria, Illinois, United States +1 more locations

COMPLETEDPhase 1/2182 miles

A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older

NCT03502707

The purpose of this study for: Cohort 1 and Cohort 2: to assess the safety and reactogenicity of the intramuscular one- and two-dose regimens, with a booster at Month 12 (Cohort 1) and to select a regimen for Cohort 3. Cohort 2 and part of Cohort 1: to assess respiratory syncytial virus (RSV) neutralizing antibody levels of the regimens containing RSV pre-fusion (preF) protein compared to the one-dose adenovirus serotype 26 respiratory syncytial virus pre-fusion (Ad26.RSV.preF) regimen. Cohort 3: to assess the safety and reactogenicity of the selected regimen and a booster at Month 12 and/or Month 24.

Janssen Vaccines & Prevention B.V.669 participantsStarted Jul 2018

Huntsville, Alabama, United States • San Diego, California, United States • Melbourne, Florida, United States +3 more locations

TERMINATEDPhase 1/2190 miles

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT02953509

The primary objectives of this study are: * To investigate the safety and tolerability, and to define the recommended Phase 2 dose and schedule (RP2DS) for magrolimab in combination with rituximab and for magrolimab in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx). * To evaluate the efficacy of magrolimab in combination with rituximab in participants with indolent lymphoma and diffuse large B-cell lymphoma (DLBCL) and to evaluate the efficacy of magrolimab in combination with R-GemOx in autologous stem cell transplant (ASCT) ineligible DLBCL participants.

Non Hodgkin Lymphoma

Gilead Sciences178 participantsStarted Nov 2016

Birmingham, Alabama, United States • Duarte, California, United States • Stanford, California, United States +17 more locations

RECRUITINGPhase 2/3292 miles

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

NCT05004129

This is an open-label phase 2/3 study for individuals with Congenital Myotonic Dystrophy (Congenital DM1) who participated in the preceding AMO-02-MD-2-003 study or individuals with either Congenital or Childhood Onset DM1 who are treatment naïve.

Congenital Myotonic Dystrophy

AMO Pharma Limited76 participantsStarted Aug 2021

Little Rock, Arkansas, United States • Los Angeles, California, United States • Palo Alto, California, United States +11 more locations

RECRUITINGNA341 miles

Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence

NCT06862648

The goal of this pivotal clinical trial is to evaluate the safety and effectiveness of the SUI-100 device for the treatment of mild-to-moderate stress urinary incontinence (SUI) in females aged 22-70 years. The main questions this study aims to answer are: 1. Does treatment with the SUI-100 device reduce SUI symptoms, as measured by urine leakage. 2. Is the device safe and effective compared to the sham group? Participants will: 1. Be randomly assigned to an active or sham control group in a blinded, multicenter study. 2. Attend treatment visits during the Treatment Phase, with SUI assessments conducted at specific intervals. 3. Enter a 3-month, treatment-free follow-up phase, with SUI assessment. 4. Proceed to three monthly maintenance treatments, followed by a final SUI assessment at study exit. The total study duration will last approximately 18 months, with each individual's participation lasting approximately 6-8 months. This study aims to provide robust data on the effectiveness, safety, and durability of the SUI-100 device for treating female Stress Urinary Incontinence.

Stress Urinary Incontinence (SUI)

Acoustic Wave Cell Therapy, Inc.130 participantsStarted Mar 2025

Phoenix, Arizona, United States • Winter Haven, Florida, United States • Boise, Idaho, United States +4 more locations

COMPLETEDPhase 2548 miles

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

NCT03406780

HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne Muscular Dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.

Muscular DystrophiesMuscular Dystrophy, DuchenneMuscular Disorders, Atrophic+5 more

Capricor Inc.20 participantsStarted Apr 2018

Sacramento, California, United States • Aurora, Colorado, United States • Orlando, Florida, United States +6 more locations

COMPLETEDPhase 1/2580 miles

Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02788045

The purpose of this study is to assess the safety/tolerability of the 2 different vaccine regimens of priming with trivalent Ad26.Mos.HIV and boosting with trivalent Ad26.Mos.HIV and Clade C gp140 plus adjuvant or priming with tetravalent Ad26.Mos4.HIV and boosting with Ad26.Mos4.HIV and Clade C glycoprotein (gp)140 plus adjuvant. Immune responses of the different vaccine schedules will be assessed.

Janssen Vaccines & Prevention B.V.201 participantsStarted Jul 2016

Birmingham, Alabama, United States • San Francisco, California, United States • Decatur, Georgia, United States +7 more locations

Active Not Recruiting587 miles

Modifiers of Disease Severity in Cerebral Cavernous Malformations

NCT01764529

Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed and cause strokes, seizures, and headaches. CCMs are often caused by an inherited gene mutation (alteration) in one of three CCM genes (CCM1, CCM2, or CCM3). There is a wide range of disease severity even among family members with this disease, though the natural history has not been clearly described for this particular population. This study will continue to enroll and follow participants with familial CCM to identify factors that influence CCM disease severity and progression, focusing on barriers to clinical trial preparedness. Our long-term goal is to identify measurable outcomes and robust biomarkers that will help select high-risk patients and help monitor drug response in future clinical trials. The specific goals of this study are to: * Identify factors that influence lesion progression to symptomatic hemorrhage and other outcomes, including quality of life; * Investigate the role of the gut microbiome and lesion burden in CCM disease, and * Identify blood biomarkers predictive of CCM disease severity and progression for clinical trials.

Cavernous Angioma, FamilialCerebral Cavernous MalformationsCerebral Cavernous Hemangioma

University of California, San Francisco800 participantsStarted Apr 2010

Phoenix, Arizona, United States • San Francisco, California, United States • Chicago, Illinois, United States +4 more locations

Active Not Recruiting592 miles

A Clinical Study on Implants With TiUltra Technology and Associated Prosthetic Components

NCT04737421

This is a multicenter, prospective, non-interventional study in which a total of 1000 subjects in need of a single, multiple or full arch restoration in any region of the mouth (healed or extracted) will be treated in up to 30 study centers. The primary aim of this study is to demonstrate non-inferiority of all NobelBiocare TiUltra implants to historic data from NobelActive TiUnite coated implant in terms of marginal bone level change over 5 years after final prosthetic delivery. Eligible subjects who provide their informed consent for participation will be enrolled into one of four groups, each sized to 250 individuals. They will be treated with the corresponding implant system assigned to the group. The allocation into a certain group is only driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic. Each subject will be followed for 5 years after definitive prosthetic placement

Marginal Bone Level Change

Nobel Biocare1,000 participantsStarted May 2021

Madison, Alabama, United States • Arlington Heights, Illinois, United States • Saint Charles, Illinois, United States +29 more locations

COMPLETED885 miles

Flexiva Pulse Registry

NCT05027971

To obtain post-market safety and efficacy data for FlexivaTM Pulse High Power Single-Use Laser Fibers during lithotripsy and soft tissue procedure of holmium laser enucleation of the prostate (HoLEP).

Urinary CalculiBenign Prostatic Hyperplasia

Boston Scientific Corporation201 participantsStarted Nov 2021

Phoenix, Arizona, United States • Miami, Florida, United States • Orlando, Florida, United States +1 more locations

TERMINATEDPhase 1/2910 miles

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

NCT03866577

The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic purpura (ITP) patients. The pharmacodynamics of the drug will be measured as platelet response in patients with ITP.

Immune Thrombocytopenic Purpura (ITP)

Momenta Pharmaceuticals, Inc.50 participantsStarted Dec 2018

Los Angeles, California, United States • Whittier, California, United States • Miami Lakes, Florida, United States +25 more locations

PreviousPage 234 of 874Next

Heart Diseasein Dallas